DGIdb - ACENOCOUMAROL Drug Record

ACENOCOUMAROL chembl:CHEMBL397420 Approved

Alternate Names:

ACENOCOUMAROL
NICOUMALONE
SINTHROME
ACENOCOUMARIN
ACENOCOUMAROLUM
ACENOCUMAROL
NITROVARFARIAN
3-(ALPHA-(P-NITROPHENOL)-BETA-ACETYLETHYL)-4-HYDROXYCOUMARIN
NICUMALON
SIN350
SINTROM®
NITROWARFARIN
ACENOKUMARIN
4-HYDROXY-3-(1-(4-NITROPHENYL)-3-OXOBUTYL)-2H-1-BENZOPYRAN-2-ONE
SINTHROME®
ACÉNOCOUMAROL
3-(ALPHA-ACETONYL-P-NITROBENZYL)-4-HYDROXYCOUMARIN
NITROPHENYLACETYLETHYL-4-HYDROXYCOUMARINE
3-(ALPHA-(4'-NITROPHENYL)-BETA-ACETYLETHYL)-4-HYDROXYCOUMARIN
4-HYDROXY-3-[1-(4-NITROPHENYL)-3-OXOBUTYL]-2H-CHROMEN-2-ONE
ACENOCUMAROLO
3-(ALPHA-ACETONYL-4-NITROBENZYL)-4-HYDROXYCOUMARIN
3-(ALPHA-P-NITROPHENYL-BETA-ACETYLETHYL)-4-HYDROXYCOUMARIN
chemidplus:152-72-7
chembl:CHEMBL397420
rxcui:154
drugbank:01418
pubchem.compound:54676537

Drug Info:

Drug Class	anticoagulants
Year of Approval	not approved by the fda
FDA Approval	not approved by the FDA
Drug Class	small molecule
Drug Indications	Anticoagulants

(1 More Sources)

Publications:

Bodin et al., 2005, Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity., Blood
Schalekamp et al., 2006, VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation., Clin. Pharmacol. Ther.
González-Conejero et al., 2007, The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol., J. Thromb. Haemost.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Rettie et al., 2006, A case study of acenocoumarol sensitivity and genotype-phenotype discordancy explained by combinations of polymorphisms in VKORC1 and CYP2C9., Br J Clin Pharmacol
Zhou et al., 2009, Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development., Curr. Med. Chem.
Montes et al., 2006, The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients., Br. J. Haematol.
Chaidaroglou A et al., 2019, Extremely low therapeutic doses of acenocoumarol in a patient with <i>CYP2C93/3</i> and <i>VKORC1-1639A/A</i> genotype., Pharmacogenomics
Serna MJ et al., 2018, Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation., Eur J Clin Invest
Ajmi M et al., 2018, Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population., Eur J Clin Pharmacol
Bryk AH et al., 2018, Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms., Vascul Pharmacol
Vandell AG et al., 2017, Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism., Heart
Misasi S et al., 2016, VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients., Medicine (Baltimore)
Pourgholi L et al., 2016, Gene polymorphisms and the risk of warfarin-induced bleeding complications at therapeutic international normalized ratio (INR)., Toxicol Appl Pharmacol
Eriksson N et al., 2016, Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy., Pharmacogenomics
Kalpana SR et al., 2017, Influence of VKORC1 and CYP2C9 Polymorphisms on Daily Acenocoumarol Dose Requirement in South Indian Patients With Mechanical Heart Valves., Clin Appl Thromb Hemost
Wakamiya T et al., 2016, Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients., Mol Diagn Ther
Sridharan K et al., 2016, Association of Genetic Polymorphisms of CYP2C9 and VKORC1 with Bleeding Following Warfarin: A Case-Control Study., Curr Clin Pharmacol
Mandic D et al., 2015, VKORC1 gene polymorphisms and adverse events in Croatian patients on warfarin therapy., Int J Clin Pharmacol Ther
Mega JL et al., 2015, Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial., Lancet
Kawai VK et al., 2014, Genotype and risk of major bleeding during warfarin treatment., Pharmacogenomics
Krishna Kumar D et al., 2015, An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population., Eur J Clin Pharmacol
Valentín II et al., 2014, Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans., P R Health Sci J
Jiménez-Varo E et al., 2014, Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm., Pharmacogenet Genomics
Wypasek E et al., 2014, Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms., Thromb Res
Hawcutt DB et al., 2014, Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects., Pharmacogenomics J
Cerezo-Manchado JJ et al., 2014, Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment., Pharmacogenomics
Jiménez-Varo E et al., 2014, Pharmacogenetics role in the safety of acenocoumarol therapy., Thromb Haemost
Shaw K et al., 2014, VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children., Pediatr Blood Cancer
Wolkanin-Bartnik J et al., 2013, Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm., Pharmacogenet Genomics
Pop TR et al., 2013, An acenocoumarol dose algorithm based on a South-Eastern European population., Eur J Clin Pharmacol
Tomek A et al., 2013, The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes., Cardiology
Gschwind L et al., 2013, Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment., Pharmacogenomics
Gaikwad T et al., 2013, Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population., Eur J Pharmacol
Krishna Kumar D et al., 2013, Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients., Thromb Res
Brehm K et al., 2013, Mechanical heart valve recipients: anticoagulation in patients with genetic variations of phenprocoumon metabolism., Eur J Cardiothorac Surg
Buzoianu AD et al., 2013, The impact of the CYP2C9 and VKORC1 polymorphisms on acenocoumarol dose requirements in a Romanian population., Blood Cells Mol Dis
van Schie RM et al., 2012, Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study., Pharmacogenomics
Giansante C et al., 2012, Oral anticoagulation and VKORC1 polymorphism in patients with a mechanical heart prosthesis: a 6-year follow-up., J Thromb Thrombolysis
Lund K et al., 2012, Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates., Br J Haematol
Smires FZ et al., 2012, Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients., J Clin Pharm Ther
van Schie RM et al., 2011, Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data., Eur Heart J
Esmerian MO et al., 2011, Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people., J Clin Pharmacol
Cadamuro J et al., 2010, Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements., Eur J Clin Pharmacol
Stepien E et al., 2009, A vitamin K epoxide reductase-oxidase complex gene polymorphism (-1639G>A) and interindividual variability in the dose-effect of vitamin K antagonists., J Appl Genet
Verde Z et al., 2009, Pharmacogenetics of acenocoumarol: CYP2C9 *2 and VKORC1 c.-1639G>A, 497C>G, 1173C>T, and 3730G>A variants influence drug dose in anticoagulated patients., Thromb Haemost
Pérez-Andreu V et al., 2009, Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy., Blood
Teichert M et al., 2009, Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period., Clin Pharmacol Ther
Markatos CN et al., 2008, VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients., Pharmacogenomics
Montes R et al., 2008, The influence of polymorphisms of VKORC1 and CYP2C9 on major gastrointestinal bleeding risk in anticoagulated patients., Br J Haematol
Spreafico M et al., 2008, Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy., Pharmacogenomics
Stehle S et al., 2008, Pharmacogenetics of oral anticoagulants: a basis for dose individualization., Clin Pharmacokinet
Meckley LM et al., 2008, An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients., Thromb Haemost
Wadelius M et al., 2009, The largest prospective warfarin-treated cohort supports genetic forecasting., Blood
van Schie RM et al., 2013, Evaluation of the effects of single-nucleotide polymorphisms in CYP3A4 and CYP4F2 on stable phenprocoumon and acenocoumarol maintenance doses., J Thromb Haemost
Teichert M et al., 2009, A genome-wide association study of acenocoumarol maintenance dosage., Hum Mol Genet
Beinema M et al., 2008, Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon., Thromb Haemost
Colàs-Campàs L et al., 2018, The rs2108622 polymorphism is related to the early risk of ischemic stroke in non-valvular atrial fibrillation subjects under oral anticoagulation., Pharmacogenomics J
Ragia G et al., 2017, Role of CYP4F2, CYP2C19, and CYP1A2 polymorphisms on acenocoumarol pharmacogenomic algorithm accuracy improvement in the Greek population: need for sub-phenotype analysis., Drug Metab Pers Ther
Lee KE et al., 2017, Influence of NR3C1 and VDR polymorphisms on stable warfarin dose in patients with mechanical cardiac valves., Int J Cardiol
Zeng WT et al., 2016, Influence of genetic polymorphisms in cytochrome P450 oxidoreductase on the variability in stable warfarin maintenance dose in Han Chinese., Eur J Clin Pharmacol
Pavani A et al., 2016, Development of neuro-fuzzy model to explore gene-nutrient interactions modulating warfarin dose requirement., Pharmacogenomics
Schooling CM, 2016, Plasma levels of vitamin K and the risk of ischemic heart disease: a Mendelian randomization study., J Thromb Haemost
Rathore SS et al., 2014, CYP4F2 1347 G > A & GGCX 12970 C > G polymorphisms: frequency in north Indians & their effect on dosing of acenocoumarol oral anticoagulant., Indian J Med Res

ACENOCOUMAROL VKORC1

Interaction Score: 59.77

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
15790782 16815313 17596133 11752352 16869821 19515014 16611310 30983536 29577257 29479633 29432897 28689179 28033245 27581200 27488176 27335128 27262824 26777610 26445138 25769357 25521356 25519826 25244877 25089947 25042728 25001883 24956252 24919870 24474498 24108193 23774941 23774101 23651023 23602689 23473641 23423913 23159639 22920394 22592842 22571356 22486182 21636598 21148049 20020283 19875892 19277427 19270263 19225451 19018719 18950464 18781852 18698879 18690342 18574025

Sources:
TdgClinicalTrial TEND PharmGKB TTD
ACENOCOUMAROL CALU

Interaction Score: 30.91

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29479633 17596133

Sources:
PharmGKB
ACENOCOUMAROL CYP4F2

Interaction Score: 23.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29479633 29432897 25519826 25089947 25042728 24956252 23510058 22486182 19578179 19270263 19132230 29273767 29252193 28262345 27488389 27462768 27061505

Sources:
PharmGKB
ACENOCOUMAROL GGCX

Interaction Score: 12.88

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29432897 25519826 25042728 24927344

Sources:
PharmGKB
ACENOCOUMAROL APOE

Interaction Score: 1.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29432897

Sources:
PharmGKB
ACENOCOUMAROL ABCB1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24919870

Sources:
PharmGKB

TEND: ACENOCOUMAROL
- Version: 01-August-2011
Alternate Names:

ACENOCOUMAROL Primary Drug Name

Drug Info:

Year of Approval not approved by the fda

Drug Class anticoagulants

Publications:
TdgClinicalTrial: ACENOCOUMAROL
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Anticoagulants

Drug Class small molecule

FDA Approval not approved by the FDA

Publications:

PharmGKB: acenocoumarol

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Wypasek E et al., 2014, Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms., Thromb Res

Lee KE et al., 2017, Influence of NR3C1 and VDR polymorphisms on stable warfarin dose in patients with mechanical cardiac valves., Int J Cardiol

Schooling CM, 2016, Plasma levels of vitamin K and the risk of ischemic heart disease: a Mendelian randomization study., J Thromb Haemost

TTD: Acenocoumarol
- Version: 2020.06.01
Alternate Names:

D05HFY TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL397420
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Trial Name	-
Novel drug target	Established target

ACENOCOUMAROL Drug Record

ACENOCOUMAROL chembl:CHEMBL397420 Approved

Alternate Names:

Drug Info:

Publications:

ACENOCOUMAROL VKORC1

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

Sources: TdgClinicalTrial TEND PharmGKB TTD

ACENOCOUMAROL CALU

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29479633 17596133

Sources: PharmGKB

ACENOCOUMAROL CYP4F2

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29479633 29432897 25519826 25089947 25042728 24956252 23510058 22486182 19578179 19270263 19132230 29273767 29252193 28262345 27488389 27462768 27061505

Sources: PharmGKB

ACENOCOUMAROL GGCX

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29432897 25519826 25042728 24927344

Sources: PharmGKB

ACENOCOUMAROL APOE

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29432897

Sources: PharmGKB

ACENOCOUMAROL ABCB1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24919870

Sources: PharmGKB

TEND: ACENOCOUMAROL

Alternate Names: ACENOCOUMAROL Primary Drug Name

Drug Info: Year of Approval not approved by the fda Drug Class anticoagulants

Publications:

TdgClinicalTrial: ACENOCOUMAROL

Alternate Names:

Drug Info: Drug Indications Anticoagulants Drug Class small molecule FDA Approval not approved by the FDA

Publications:

PharmGKB: acenocoumarol

Alternate Names:

Drug Info:

TTD: Acenocoumarol

Alternate Names: D05HFY TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL397420

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Sources:
TdgClinicalTrial TEND PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
29479633 17596133

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29479633 29432897 25519826 25089947 25042728 24956252 23510058 22486182 19578179 19270263 19132230 29273767 29252193 28262345 27488389 27462768 27061505

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29432897 25519826 25042728 24927344

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29432897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24919870

Sources:
PharmGKB

Alternate Names:

ACENOCOUMAROL Primary Drug Name

Drug Info:

Year of Approval not approved by the fda

Drug Class anticoagulants

Drug Info:

Drug Indications Anticoagulants

Drug Class small molecule

FDA Approval not approved by the FDA

Alternate Names:

D05HFY TTD Drug ID